VALBIOTIS announces positive results from phase IIA trial of VALEDIA in prediabetics

This article was originally published here

In this population, VALEDIA significantly reduced fasting and post-prandial blood glucose levels, the two main risk factors for type 2 diabetes and the primary and secondary endpoints of

The post VALBIOTIS announces positive results from phase IIA trial of VALEDIA in prediabetics appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply